Skip to main content

Table 1 Characteristics of patients with thyroid cancer and their controls

From: No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study

  

Cases (%) (n = 1229)

Controls (%) (n = 7374)

Crude OR (95 % CI)

Age (years)

<40

335 (27.3)

2010 (27.3)

-

 

40–59

455 (37.0)

2745 (37.2)

-

 

60–69

206 (16.8)

1200 (16.3)

-

 

70–79

174 (14.2)

1064 (14.4)

-

 

≥80

59 (4.8)

355 (4.8)

-

Sex

Male

314 (25.6)

1884 (25.6)

-

 

Female

915 (74.5)

5490 (74.5)

-

BMI

<25

435 (35.4)

2717 (36.9)

1.00 (referent)

 

25–29.9

337 (27.4)

1977 (26.8)

1.07 (0.92–1.26)

 

30–59.9

245 (19.9)

1222 (16.6)

1.27 (1.07–1.51)

 

Unknown

212 (17.3)

1458 (19.8)

0.85 (0.69–1.04)

Smoking

Non-smoker

693 (56.4)

3603 (48.9)

1.00 (referent)

 

Current

182 (14.8)

1406 (19.1)

0.66 (0.55–0.79)

 

Past

235 (19.1)

1560 (21.2)

0.78 (0.66–0.92)

 

Unknown

119 (9.7)

805 (10.9)

0.72 (0.55–0.92)

Alcohol consumption

None

244 (19.9)

1233 (16.7)

1.00 (referent)

 

Current

819 (66.6)

4989 (67.7)

0.81 (0.69–0.96)

 

Past

13 (1.1)

74 (1.0)

0.88 (0.48–1.62)

 

Unknown

153 (12.5)

1078 (14.6)

0.67 (0.52–0.85)

Hypothyroidism

No

1157 (94.1)

7022 (95.2)

1.00 (referent)

 

Yes

72 (5.9)

352 (4.8)

1.25 (0.96–1.63)

Hyperthyroidism

No

1195 (97.2)

7284 (98.8)

1.00 (referent)

 

Yes

34 (2.8)

90 (1.2)

2.29 (1.54–3.42)

Goitera

No

1129 (91.9)

7313 (99.2)

1.00 (referent)

 

Yes

100 (8.1)

61 (0.8)

10.60 (7.62–14.74)

Diabetes mellitus

No

1159 (94.3)

7009 (95.1)

1.00 (referent)

 

Yes

70 (5.7)

365 (5.0)

1.17 (0.89–1.54)

 

DM durationb < 4 ys.

24 (34.3)

142 (33.9)

1.00 (referent)

 

DM durationb 4–8 ys.

18 (25.7)

133 (31.7)

0.71 (0.32–1.60)

 

DM durationb > 8 ys.

28 (40.0)

144 (34.4)

1.22 (0.60–2.51)

 

A1c <53 mmol/l (7 %)

32 (45.7)

175 (41.8)

1.00 (referent)

 

A1c ≥ 53 mmol/l (7 %)

32 (45.7)

217 (51.8)

0.80 (0.46–1.38)

 

Unknown A1c level

6 (8.6)

27 (6.4)

1.24 (0.44–3.48)

CHF

No

1217 (99.0)

7283 (98.8)

1.00 (referent)

 

Yes

12 (1.0)

91 (1.2)

0.78 (0.42–1.45)

IHD

No

1160 (94.4)

6934 (94.0)

1.00 (referent)

 

Yes

69 (5.6)

440 (6.0)

0.93 (0.70–1.23)

Hypertension

No

968 (78.8)

5918 (80.3)

1.00 (referent)

 

Yes

261 (21.2)

1456 (19.8)

1.13 (0.95–1.34)

Stroke/TIA

No

1198 (97.5)

7147 (96.9)

1.00 (referent)

 

Yes

31 (2.5)

227 (3.1)

0.81 (0.55–1.19)

Dyslipidemia

No

1144 (93.1)

6800 (92.2)

1.00 (referent)

 

Yes

85 (6.9)

574 (7.8)

0.86 (0.67–1.11)

NSAID

No prior use

518 (42.2)

3083 (41.8)

1.00 (referent)

 

1–4 Rx.

447 (36.4)

2740 (37.2)

0.97 (0.84–1.12)

 

≥5 Rx.

264 (21.5)

1551 (21.0)

1.02 (0.85–1.21)

ASA

No prior use

1065 (86.7)

6365 (86.3)

1.00 (referent)

 

1–14 Rx.

78 (6.4)

481 (6.5)

0.96 (0.75–1.25)

 

≥15 Rx.

86 (7.0)

528 (7.2)

0.96 (0.74–1.26)

Statins

No prior use

1078 (87.7)

6453 (87.5)

1.00 (referent)

 

1–14 Rx.

47 (3.8)

337 (4.6)

0.83 (0.60–1.15)

 

≥15 Rx.

104 (8.5)

584 (7.9)

1.07 (0.83–1.38)

  1. A1c = glycated hemoglobin, assessed for diabetics only, ‘unknown’ level includes recordings earlier than 1 year before the cancer diagnosis
  2. OR odds ratio, CI confidence interval, BMI body mass index, CHF congestive heart failure, IHD ischemic heart disease, TIA transient ischemic attack, NSAID non-steroidal anti-inflammatory drugs, ASA acetylsalicylic acid
  3. aGoiter includes toxic and nontoxic forms
  4. bAnalysis restricted to cases and controls with a recorded diagnosis of diabetes mellitus